Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
416 studies found for:    Open Studies | "Myelodysplastic Syndromes"
Show Display Options
Rank Status Study
21 Recruiting Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: Antibiotic and antifungal drugs
22 Unknown  Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
Condition: Myelodysplastic Syndrome
Interventions: Drug: Azacitidine for Injection;   Drug: Vidaza®
23 Unknown  Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: 5-Azacytidine and Lenalidomide
24 Not yet recruiting Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy
Condition: Myelodysplastic Syndrome
Interventions: Drug: BSC;   Drug: HIDRA/VPA
25 Unknown  Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Genetic: DNA methylation analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis
26 Recruiting Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Conditions: Hemochromatosis;   Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Other: Venesection
27 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
28 Recruiting Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Lenalidomide;   Other: Placebo
29 Recruiting Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndrome
Interventions: Drug: Decitabine;   Drug: Vorinostat;   Biological: Interleukin-2;   Other: Natural killer (NK) cells
30 Unknown  Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
Conditions: Myelodysplastic Syndromes;   Juvenile Myelomonocytic Leukemia
Intervention:
31 Recruiting Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: dasatinib (SPRYCEL);   Drug: all trans retinoic acid (VESANOID)
32 Unknown  Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Drug: clofarabine;   Drug: cytarabine;   Drug: idarubicin
33 Recruiting Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Cladribine;   Procedure: Stem Cell Transplant;   Drug: G-CSF;   Drug: Methotrexate
34 Unknown  The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality
Condition: Myelodysplastic Syndromes
Intervention: Drug: lenalidomide
35 Not yet recruiting Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Intervention: Drug: CPI-613
36 Recruiting T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes
Intervention: Procedure: CD8+ T-cell depleted donor lymphocyte infusion
37 Not yet recruiting Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention: Drug: AS101
38 Recruiting Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Intervention: Drug: Oral Azacitidine
39 Recruiting Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Conditions: Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Chronic
Intervention: Other: Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
40 Recruiting Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
Conditions: Myelodysplasia;   Myelofibrosis;   Aplastic Anemia
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years